Literature DB >> 16572459

Localization and characterization of pituitary adenylate cyclase-activating polypeptide receptors in the human cerebellum during development.

Magali Basille1, Dorthe Cartier, David Vaudry, Isabelle Lihrmann, Alain Fournier, Pierre Freger, Nicole Gallo-Payet, Hubert Vaudry, Bruno Gonzalez.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) receptors are actively expressed in the cortical layers of the cerebellum of rodents and contribute to cerebellar development. The present report provides the first anatomical localization and characterization of PACAP receptors in the developing human cerebellum. RT-PCR analysis from 15-week-old fetuses to 22-year-old subject showed that PAC1-R and VPAC1-R are expressed in the cerebellum at all stages, whereas VPAC2-R mRNA was barely detectable. In situ hybridization labeling indicated that, in human fetuses, PAC1-R mRNA is associated with the external granule cell layer (EGL), a germinative neuroepithelium, and with the internal granule cell layer (IGL). The distribution pattern of VPAC1-R mRNA was very similar to that of PAC1-R mRNA, whereas VPAC2-R mRNA was visualized only in 7-22-year-old subjects. The localization of [(125)I]PACAP27 binding sites was fully consistent with the distribution of PAC1-R and VPAC1-R mRNA. Pharmacological characterization revealed that, in the EGL and IGL from 15-24-week-old fetuses and in the granule cell layer from 7-22-year-old patients, binding sites exhibit a PAC1-R profile. In contrast, PACAP binding sites observed in the molecular layer and medulla of the adult cerebellum consisted of a heterogeneous population of PAC1-R and VPAC(1/2)-R. Altogether, these data provide the first evidence that PACAP receptors are expressed in the human cerebellar cortex. PAC1-R is the predominant PACAP receptor found in fetuses, and both PAC1-R and VPAC1-R are expressed in the mature cerebellum. These observations suggest that PACAP has neurodevelopmental functions in the human cerebellum.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16572459     DOI: 10.1002/cne.20934

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  13 in total

1.  Changes in the expression of PACAP-like compounds during the embryonic development of the earthworm Eisenia fetida.

Authors:  Akos Boros; Dora Reglodi; Zsofia Herbert; Gabor Kiszler; Jozsef Nemeth; Andrea Lubics; Peter Kiss; Andrea Tamas; Seiji Shioda; Kouhei Matsuda; Edit Pollak; Laszló Molnar
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

2.  PACAP enhances barrier properties of cerebral microvessels.

Authors:  Imola Wilhelm; Csilla Fazakas; Andrea Tamás; Gábor Tóth; Dóra Reglődi; István A Krizbai
Journal:  J Mol Neurosci       Date:  2014-03-11       Impact factor: 3.444

3.  Cerebellar cortical-layer-specific control of neuronal migration by pituitary adenylate cyclase-activating polypeptide.

Authors:  D B Cameron; L Galas; Y Jiang; E Raoult; D Vaudry; H Komuro
Journal:  Neuroscience       Date:  2007-03-23       Impact factor: 3.590

Review 4.  Interactions of PACAP and ceramides in the control of granule cell apoptosis during cerebellar development.

Authors:  A Falluel-Morel; N Aubert; D Vaudry; A Desfeux; A Allais; D Burel; M Basille; H Vaudry; V Laudenbach; B J Gonzalez
Journal:  J Mol Neurosci       Date:  2008-06-24       Impact factor: 3.444

5.  Interaction of PACAP with Sonic hedgehog reveals complex regulation of the hedgehog pathway by PKA.

Authors:  Pawel Niewiadomski; Annie Zhujiang; Mary Youssef; James A Waschek
Journal:  Cell Signal       Date:  2013-07-18       Impact factor: 4.315

Review 6.  Role of PACAP in controlling granule cell migration.

Authors:  Donald Bryant Cameron; Emilie Raoult; Ludovic Galas; Yulan Jiang; Kimberly Lee; Taofang Hu; David Vaudry; Hitoshi Komuro
Journal:  Cerebellum       Date:  2009-06-23       Impact factor: 3.847

7.  Vasoactive intestinal polypeptide immunoreactivity in the human cerebellum: qualitative and quantitative analyses.

Authors:  Vincenzo Benagiano; Paolo Flace; Loredana Lorusso; Anna Rizzi; Lorenzo Bosco; Raffaele Cagiano; Glauco Ambrosi
Journal:  J Anat       Date:  2009-06-22       Impact factor: 2.610

8.  VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models.

Authors:  Jeremiah Hadwen; Duncan MacKenzie; Fahad Shamim; Kevin Mongeon; Martin Holcik; Alex MacKenzie; Faraz Farooq
Journal:  Orphanet J Rare Dis       Date:  2014-01-09       Impact factor: 4.123

Review 9.  Cellular commitment in the developing cerebellum.

Authors:  Hassan Marzban; Marc R Del Bigio; Javad Alizadeh; Saeid Ghavami; Robby M Zachariah; Mojgan Rastegar
Journal:  Front Cell Neurosci       Date:  2015-01-12       Impact factor: 5.505

10.  How does angiotensin AT(2) receptor activation help neuronal differentiation and improve neuronal pathological situations?

Authors:  Marie-Odile Guimond; Nicole Gallo-Payet
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-19       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.